ISO 10993 Biocompatibility Testing for Wearables: Full Cost & Timeline Breakdown

If your device touches skin for more than 30 days, ISO 10993 is not optional. It is the regulatory expectation on every continent. Yet for many wearable brands entering the medical market, biocompatibility is the requirement they learn about last — often during a submission review, when the notified body asks for a biological evaluation report that does not exist.

This article covers what ISO 10993 testing actually requires for wearable devices, how to determine which tests apply to your product, the real cost of each test, the timeline from sample submission to final report, and how chemical characterization under ISO 10993-18 can reduce — but not eliminate — the need for animal testing. For deeper analysis of the subsequent regulatory steps, see our complete breakdown of the Medical Wearable FDA 510(k) submission cost and timeline for OEM partners.

Why “Skin Contact” Triggers a Regulatory Obligation

The ISO 10993 series applies to any medical device that has direct or indirect contact with the patient. For wearable devices, the relevant contact classification is surface device, intact skin, limited contact (≤ 24 hours), prolonged contact (24 hours to 30 days), or permanent contact (> 30 days).

A smartwatch worn 24/7 is a permanent-contact surface device. A smart ring worn during sleep tracking is a prolonged-contact device. An ECG patch worn for 72 hours is a prolonged-contact device. All three require biological evaluation.

The regulatory trigger is not whether the device is “invasive” — it is whether the device contacts the patient. Skin is the largest organ in the human body, and prolonged contact with a material that leaches irritants, sensitizers, or cytotoxic compounds can cause harm that manifests weeks or months after first use.

The ISO 10993 Standard Family: A Map

ISO 10993 is not a single standard. It is a family of over 20 parts, each addressing a different aspect of biological evaluation. For wearable devices, the following parts are most relevant:

Determining Your Test Matrix: Contact Type × Duration

ISO 10993-1 provides an endpoint matrix that maps contact type and duration to required biological endpoints. For a wearable device with intact skin contact, the matrix yields:

For a typical smartwatch or smart ring with permanent skin contact, the minimum test package is: cytotoxicity + sensitization + irritation. Additional endpoints are evaluated on a case-by-case basis depending on the materials, manufacturing process, and chemical characterization results.

Cost Breakdown: What Each Test Actually Costs

The following costs are based on 2026 pricing from GLP-accredited laboratories in the US, EU, and China. Prices vary by lab, sample preparation complexity, and whether the test is performed under GLP (required for regulatory submissions).

Total for a typical wearable baseline package (cytotoxicity + sensitization + irritation): $5,800-$11,500, 8-12 weeks.

Total with chemical characterization and toxicological assessment: $13,800-$31,500, 14-20 weeks. The wide range reflects the difference between a simple device with known materials and a complex device with multiple material families, coatings, adhesives, and colorants.

Chemical Characterization: The Smartest Money You Can Spend

ISO 10993-18 chemical characterization is not a biological test. It is an analytical chemistry exercise: extract the device in solvents that simulate the body environment, then analyze the extract using gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS) to identify and quantify every chemical that leaches out.

Why invest in chemical characterization when it is technically optional? Three reasons:

1. It can reduce the biological testing burden. If chemical characterization demonstrates that no leachables exceed the analytical evaluation threshold (AET), and toxicological risk assessment (ISO 10993-17) confirms that identified leachables are below toxicologically relevant thresholds, some biological endpoints can be waived. This is explicitly allowed under ISO 10993-1 and is increasingly accepted by FDA and EU notified bodies.
2. It identifies problems before biological testing. A cytotoxicity test costs $800-$1,500 and takes 2-3 weeks. If it fails, you need to identify the problematic material, reformulate, and retest. Chemical characterization can identify problematic extractables before the biological test cycle begins, saving both time and money.
3. It is becoming the regulatory expectation. EU MDR requires a biological evaluation plan and report as part of the technical documentation. Chemical characterization is the preferred method for demonstrating that the biological evaluation is based on a thorough understanding of the device’s material composition. Submissions without chemical characterization face more scrutiny and more requests for additional information.

FDA vs EU MDR: Key Differences in Biocompatibility Expectations

Common Failure Modes and What They Cost to Fix

Nickel release from stainless steel components

Stainless steel is not inherently nickel-free. Even 316L surgical stainless steel contains 10-14% nickel, and under prolonged skin contact with sweat, nickel can leach. The sensitization test detects this, and a positive result requires either switching to a nickel-free alloy (titanium, 904L stainless steel) or applying a barrier coating — both of which involve tooling changes and re-validation.

Cost to fix: $5,000-$15,000 in material and tooling changes, plus 8-12 weeks re-testing.

Silicone curing agent residues

Silicone watch bands and seals are manufactured with peroxide or platinum catalysts. Incomplete curing leaves residual curing agents that can be cytotoxic or sensitizing. A post-cure process (additional heat treatment after molding) resolves most cases, but if the base silicone formulation is incompatible with skin contact, the entire material must be re-sourced.

Cost to fix: Post-cure process validation: $2,000-$5,000. Material re-sourcing: $10,000-$30,000 plus tooling changes.

Adhesive and coating leachables

The adhesives used to bond display modules, seal enclosures, and attach sensors are a common source of unexpected leachables. Many industrial adhesives are not formulated for prolonged skin contact. Chemical characterization often identifies adhesive leachables that were not disclosed on the material datasheet because the manufacturer never intended the adhesive for medical use.

Cost to fix: Adhesive substitution: $3,000-$8,000 in process re-validation. Worst case: re-design of the bonding method: $15,000-$40,000.

Material Selection: Three Categories, Three Pathways

Housing and enclosure materials

Typical materials: stainless steel, titanium, aluminum, polycarbonate, ABS, nylon. The key variable is metal ion release (nickel, chromium, cobalt). For metal housings, request the material’s composition certificate and verify that it meets the nickel release limits in EN 1811 if marketed in the EU. For plastic housings, request the resin supplier’s ISO 10993 test data — many medical-grade resins are pre-tested, which can reduce your testing scope.

Band and strap materials

Typical materials: silicone, TPU, fluoroelastomer, woven nylon, leather. Silicone and TPU are the most common for medical wearables because they are inert, cleanable, and available in medical-grade formulations. The key risk is plasticizer and curing agent leaching. Always specify medical-grade silicone (e.g., USP Class VI or ISO 10993 tested) rather than industrial-grade — the cost difference is approximately $0.50-$1.50 per band, and the testing cost avoidance is 10-50x that. For deeper analysis, see our comprehensive guide on skin safety and biocompatibility in medical wearables.

Sensor electrode materials

Typical materials: stainless steel, conductive silicone, silver/silver chloride (Ag/AgCl). Electrodes present the highest biocompatibility risk because they are in direct, prolonged electrical contact with skin. Ag/AgCl electrodes require particular attention — silver is a known sensitizer, and the chloride component can cause local irritation. Electrode materials should be the first item submitted for biocompatibility testing, not the last.

The Biological Evaluation Plan (BEP): What to Document Before the Lab Gets Your Samples

A Biological Evaluation Plan is not a form you fill out the week before sending samples to the lab. It is a structured document that defines your testing strategy before any test begins. Under ISO 10993-1:2018, the BEP is the starting point of the biological evaluation process — and under EU MDR, it is a required component of the technical documentation. A BEP for a wearable device should address the following:

Device description and intended use

Include the device’s physical configuration, materials of construction, manufacturing processes, and the nature and duration of body contact. A smart ring worn on the finger 24/7 has a different biological risk profile than a chest-worn ECG patch used for 72 hours. Similarly, a wrist-worn continuous ECG monitoring smartwatch utilizing medical-grade sensors for heart rhythm assessment requires precise documentation of its strap and casing materials over prolonged skin contact. The BEP must justify why the contact classification was assigned — and the justification must reference the specific ISO 10993-1 contact categories, not a generic description of how the device is worn.

Material characterization summary

List every material that contacts the patient: housing, band, sensor electrodes, adhesives, coatings, and any processing aids that could leave residues. For each material, reference the supplier’s composition disclosure and any existing biocompatibility data. The FDA’s 2023 guidance on ISO 10993-1 explicitly states that leveraging existing data from material suppliers is acceptable when the data is relevant to the device’s specific manufacturing process and contact conditions. However, the guidance also warns that supplier data alone is rarely sufficient — the brand owner must demonstrate that the supplier’s testing conditions are equivalent to the device’s actual use conditions.

Gap analysis

Compare available test data against the ISO 10993-1 endpoint matrix. Identify which endpoints are covered by existing data, which require new testing, and which can be addressed through chemical characterization and toxicological risk assessment. The gap analysis is the logical bridge between the material data you have and the test data you need — and it is the section most frequently challenged by notified body reviewers. A gap analysis that simply states “no data available, all tests required” without evaluating whether chemical characterization could reduce the testing burden will be questioned.

Test strategy and justification

For each endpoint requiring new testing, specify the test method, the sample preparation protocol, the extraction conditions, and the acceptance criteria. If you are proposing to waive a biological endpoint based on chemical characterization data, provide the toxicological rationale with reference to ISO 10993-17 thresholds. The FDA expects this justification to be data-driven; a statement that “the material is known to be biocompatible” without supporting evidence will result in a deficiency letter. A qualified toxicologist should review the BEP before it is finalized — the cost of the review is a fraction of the cost of a rejected submission.

Risk management integration

The BEP must reference the device’s risk management file per ISO 14971. Biological hazards identified in the risk analysis should map to specific tests in the BEP. If the risk analysis identifies nickel sensitization as a hazard, the BEP must address how that hazard is evaluated — whether through material composition review, chemical characterization for nickel release, or sensitization testing. A BEP that operates in isolation from the risk management file is a regulatory vulnerability.

A complete BEP, reviewed by a qualified toxicologist before submission, typically takes 2-4 weeks to prepare. The investment is modest compared to the cost of a rejected submission or a retest cycle triggered by an incomplete test strategy.

How Biocompatibility Fits Into the 510(k) and CE Marking Dossier

Biocompatibility is not a standalone activity. It is a section of your regulatory submission, and the format and depth expected by FDA and EU notified bodies differ in ways that affect how you structure your testing program.

FDA 510(k) submissions

The biocompatibility section of a 510(k) is part of the substantial equivalence demonstration. The FDA reviewer compares your biocompatibility testing to the predicate device’s testing. If your device uses the same materials and the same manufacturing process as a predicate, and the predicate’s biocompatibility testing was accepted, you may be able to reference the predicate’s testing rather than repeating it. However, the FDA’s 2023 guidance clarifies that material equivalence must be demonstrated with composition data, not asserted — and the burden of proof is on the submitter.

The FDA expects biocompatibility testing to be performed on the finished device, not on component materials in isolation. If your device is sterilized, the testing must be performed on sterilized samples. If your device is supplied with a charger or accessory that contacts the patient, those components must be included in the evaluation. A common 510(k) deficiency is biocompatibility testing on non-sterilized samples for a device that is sold sterile — the sterilization process can alter material surface chemistry, and the FDA knows this. According to the FDA’s 2023 annual report on 510(k) quality, biocompatibility was among the top 10 reasons for Refuse to Accept (RTA) decisions.

EU MDR CE marking

Under MDR Annex I, General Safety and Performance Requirement (GSPR) 10, the biological evaluation must address not only the materials but also the substances that may be released from the device — including wear debris, degradation products, and manufacturing residues. The MDR’s emphasis on chemical characterization is not optional; it is the expected methodology for demonstrating that the device does not release harmful substances over its intended lifetime.

The MDR also requires the biological evaluation to be updated as part of post-market surveillance. If a material supplier changes a formulation, or if a new manufacturing process is introduced, the biological evaluation must be re-assessed. This is different from the FDA approach, where post-market changes are evaluated through the change control process and may or may not require a new 510(k) — but the biocompatibility data is not automatically re-reviewed unless the change could affect safety or effectiveness.

For devices entering both markets, the practical implication is that a single testing program can support both FDA and EU MDR submissions — but the Biological Evaluation Plan and Biological Evaluation Report must be written to address the specific expectations of each regulator. The FDA wants to see substantial equivalence. The EU notified body wants to see a comprehensive, chemistry-driven safety assessment. A well-designed BEP anticipates both.

Frequently Asked Questions

Do smartwatches and fitness trackers need ISO 10993 biocompatibility testing?

If marketed as general wellness products with no medical claims, ISO 10993 testing is not strictly required — but it is strongly recommended for any device worn continuously on skin. If the device makes any medical claim (heart rate monitoring for clinical use, SpO₂ for health assessment, ECG for arrhythmia detection), ISO 10993 evaluation is required by both FDA and EU MDR. The safest approach is to conduct at minimum cytotoxicity and irritation testing for any device with prolonged skin contact.

How much does ISO 10993 biocompatibility testing cost?

A baseline package of cytotoxicity, sensitization, and irritation testing costs $5,800-$11,500 and takes 8-12 weeks. Adding chemical characterization (ISO 10993-18) and toxicological risk assessment (ISO 10993-17) brings the total to $13,800-$31,500 over 14-20 weeks. The wide range reflects differences in device complexity, number of materials, and whether pre-existing test data from material suppliers can be leveraged.

Are cytotoxicity, sensitization, and irritation all required for wearable devices?

For devices with prolonged or permanent skin contact, all three are required by ISO 10993-1. Cytotoxicity is required for all skin-contact devices regardless of duration. Sensitization and irritation are required for contact exceeding 24 hours. For limited-contact devices (≤ 24 hours), sensitization and irritation are evaluated on a case-by-case basis, but most notified bodies will expect them to be addressed in the biological evaluation.

Can chemical characterization (ISO 10993-18) replace biological testing?

Chemical characterization can reduce the biological testing burden but cannot fully replace it. If chemical characterization and toxicological risk assessment demonstrate that all identified leachables are below toxicologically relevant thresholds, some biological endpoints may be waived per ISO 10993-1. However, cytotoxicity testing is almost always required regardless of chemical characterization results. EU notified bodies are increasingly accepting chemical characterization as the primary evidence for biological safety, but this requires a thorough, well-documented evaluation.

What is the difference between FDA and CE MDR biocompatibility requirements?

Both FDA and EU MDR require compliance with ISO 10993, but EU MDR places greater emphasis on chemical characterization (ISO 10993-18), requires a formal Biological Evaluation Plan and Report in the technical documentation, and prefers in vitro test methods (ISO 10993-23) over animal testing. FDA accepts the ISO 10993-1 endpoint matrix, strongly recommends chemical characterization for all devices, and provides specific guidance on biocompatibility for 510(k) submissions.

Planning biocompatibility testing for your wearable device? Our team works with ISO 10993-accredited laboratories and can provide material documentation, sample preparation, and regulatory guidance to streamline your submission. Contact us to discuss your testing requirements.